Schneider Verena, Lévesque Linda E, Zhang Bin, Hutchinson Thomas, Brophy James M
Division of Clinical Epidemiology, Royal Victoria Hospital, Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Am J Epidemiol. 2006 Nov 1;164(9):881-9. doi: 10.1093/aje/kwj331. Epub 2006 Sep 27.
Conventional nonsteroidal antiinflammatory drugs (NSAIDs) are associated with acute renal failure, but cyclooxygenase-2 inhibitors have not been comparatively evaluated. The authors conducted a nested case-control study to assess the association between exposure to NSAIDs, including cyclooxygenase-2 inhibitors, and hospitalization for acute renal failure. They identified 121,722 new NSAID users older than age 65 years from the administrative health care databases of Quebec, Canada, in 1999-2002. Data for 4,228 cases and 84,540 controls matched on age and follow-up time were analyzed by using conditional logistic regression, adjusted for sex, age, health status, health care utilization measures, exposure to contrast agents, and nephrotoxic medications. The risk of acute renal failure for all NSAIDs combined was highest within 30 days of treatment initiation (adjusted rate ratio (RR) = 2.05, 95% confidence interval (CI): 1.61, 2.60) and receded thereafter. The association with acute renal failure within 30 days of therapy initiation was comparable for rofecoxib (RR = 2.31, 95% CI: 1.73, 3.08), naproxen (RR = 2.42, 95% CI: 1.52, 3.85), and nonselective, non-naproxen NSAIDs (RR = 2.30, 95% CI: 1.60, 3.32) but was borderline lower for celecoxib (RR =1.54, 95% CI: 1.14, 2.09; test for interaction comparing celecoxib with rofecoxib, p = 0.057). There was a significant association for both selective and nonselective NSAIDs with acute renal failure, but confirmatory studies are required.
传统非甾体抗炎药(NSAIDs)与急性肾衰竭相关,但环氧化酶-2抑制剂尚未得到比较评估。作者进行了一项巢式病例对照研究,以评估使用包括环氧化酶-2抑制剂在内的NSAIDs与因急性肾衰竭住院之间的关联。他们从加拿大魁北克省1999 - 2002年的行政医疗保健数据库中识别出121722名65岁以上的新NSAIDs使用者。通过条件逻辑回归分析了4228例病例和84540例年龄及随访时间匹配的对照的数据,并对性别、年龄、健康状况、医疗保健利用指标、造影剂暴露和肾毒性药物进行了校正。所有NSAIDs联合使用导致急性肾衰竭的风险在治疗开始后30天内最高(校正率比(RR)= 2.05,95%置信区间(CI):1.61,2.60),此后逐渐下降。罗非昔布(RR = 2.31,95% CI:1.73,3.08)、萘普生(RR = 2.42,95% CI:1.52,3.85)和非选择性、非萘普生类NSAIDs(RR = 2.30,95% CI:1.60,3.32)在治疗开始后30天内与急性肾衰竭的关联相当,但塞来昔布的关联略低(RR = 1.54,95% CI:1.14,2.09;塞来昔布与罗非昔布交互作用检验,p = 0.057)。选择性和非选择性NSAIDs与急性肾衰竭均存在显著关联,但仍需进行验证性研究。